Keyword: TCR2 Therapeutics

TCR2 Therapeutics has priced its IPO at the midpoint of the target range. The offering stands to net TCR2 $67 million.

Barely a year after pulling in $125 million to advance a pair of T-cell therapies, TCR2 Therapeutics is looking to raise up to $80 million in an IPO.

Athenex is picking up $100 million, licensing a cancer-fighting enzyme and launching a new Chinese joint venture built around T-cell receptor tech.

Former Ariad CEO leads Roivant and Arbutus' new RNA JV, Purdue Pharma names new R&D head, Immunomedics poaches AZ I-O exec as R&D chief.

The funds will carry TCR2 into 2021, allowing it to bring its lead asset through clinical proof of concept.

Armed with debut financing of $44.5 million, Cambridge-based startup TCR2 Therapeutics is poised to advance its cell-based cancer therapies toward the clinic.